BC Extra | Aug 2, 2019
Company News

Aug. 1 Company Quick Takes: Nektar gains on breakthrough for NKTR-214; plus Adaptive's MRD test, Acadia, Vanda and more

Nektar gains after FDA breakthrough therapy designation  Nektar Therapeutics Inc. (NASDAQ:NKTR) was up $2.73 (10%) to $31.19 after FDA granted breakthrough designation for bempegaldesleukin (NKTR-214) in combination with Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY)...
BC Extra | Jul 2, 2019
Company News

July 2 Company Quick Takes: Gilead's Truvada REMS removed; plus UC, Amicus/Paragon and Iovance

FDA removes REMS for Truvada  FDA said it is eliminating the REMS for Truvada emtricitabine/tenofovir from Gilead Sciences Inc. (NASDAQ:GILD) and its four generics approved for pre-exposure prophylaxis (PrEP), which required manufacturers to provide educational...
BC Extra | May 28, 2019
Company News

May 28 Company Quick Takes: Viela finds China partner for rare CNS disorder mAb; plus Santhera, Juvenescence’s Souvien and more

Viela partners with Hansoh on mAb for rare CNS disorder in China  Viela Bio Inc. (Gaithersburg, Md.) granted Hansoh Pharmaceutical Group Co. Ltd. (Lianyungang, China) rights to develop and commercialize Viela's humanized anti-CD19 mAb inebilizumab...
BC Week In Review | Apr 26, 2019
Company News

UC group issued foundational CRISPR patent in U.S.

The USPTO issued to The Regents of the University of California, the University of Vienna and Emmanuelle Charpentier the core foundational CRISPR patent that was involved in a patent interference case between the UC Regents...
BC Week In Review | Apr 5, 2019
Company News

UC group strengthens CRISPR IP position in Europe

The European Patent Office issued a third patent covering broad CRISPR-Cas9 technology Wednesday to The Regents of the University of California, the University of Vienna and Emmanuelle Charpentier, further strengthening the group's IP position in...
BC Extra | Mar 12, 2019
Company News

UC strengthens CRISPR IP position with new patent

The USPTO issued a third patent covering fundamental aspects of the CRISPR-Cas9 technology to The Regents of the University of California, the University of Vienna and Emmanuelle Charpentier, strengthening the group's patent position in the...
BC Extra | Feb 8, 2019
Company News

USPTO to grant UC foundational CRISPR patent

A notice of allowance on a core CRISPR patent application will put IP covering the most foundational aspects of the game-changing gene editing technology in the hands of two rival parties. The Regents of the...
BC Week In Review | Nov 2, 2018
Company News

UC Regents issued second CRISPR patent in U.S.

The Regents of the University of California, the University of Vienna and Emmanuelle Charpentier were granted a patent by the U.S. Patent Office covering use of guide RNA formats in CRISPR-Cas9 gene editing technology. The...
BC Innovations | Nov 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: October 2018

New Therapeutic Targets and Biomarkers: October 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during October. Therapeutic targets are defined as any protein, gene or other molecule...
BC Extra | Oct 30, 2018
Company News

UC Regents issued second CRISPR patent in U.S.

The Regents of the University of California, the University of Vienna and Emmanuelle Charpentier were granted a patent by the U.S. Patent Office covering use of guide RNA formats in CRISPR-Cas9 gene editing technology. The...
Items per page:
1 - 10 of 90
BC Extra | Aug 2, 2019
Company News

Aug. 1 Company Quick Takes: Nektar gains on breakthrough for NKTR-214; plus Adaptive's MRD test, Acadia, Vanda and more

Nektar gains after FDA breakthrough therapy designation  Nektar Therapeutics Inc. (NASDAQ:NKTR) was up $2.73 (10%) to $31.19 after FDA granted breakthrough designation for bempegaldesleukin (NKTR-214) in combination with Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY)...
BC Extra | Jul 2, 2019
Company News

July 2 Company Quick Takes: Gilead's Truvada REMS removed; plus UC, Amicus/Paragon and Iovance

FDA removes REMS for Truvada  FDA said it is eliminating the REMS for Truvada emtricitabine/tenofovir from Gilead Sciences Inc. (NASDAQ:GILD) and its four generics approved for pre-exposure prophylaxis (PrEP), which required manufacturers to provide educational...
BC Extra | May 28, 2019
Company News

May 28 Company Quick Takes: Viela finds China partner for rare CNS disorder mAb; plus Santhera, Juvenescence’s Souvien and more

Viela partners with Hansoh on mAb for rare CNS disorder in China  Viela Bio Inc. (Gaithersburg, Md.) granted Hansoh Pharmaceutical Group Co. Ltd. (Lianyungang, China) rights to develop and commercialize Viela's humanized anti-CD19 mAb inebilizumab...
BC Week In Review | Apr 26, 2019
Company News

UC group issued foundational CRISPR patent in U.S.

The USPTO issued to The Regents of the University of California, the University of Vienna and Emmanuelle Charpentier the core foundational CRISPR patent that was involved in a patent interference case between the UC Regents...
BC Week In Review | Apr 5, 2019
Company News

UC group strengthens CRISPR IP position in Europe

The European Patent Office issued a third patent covering broad CRISPR-Cas9 technology Wednesday to The Regents of the University of California, the University of Vienna and Emmanuelle Charpentier, further strengthening the group's IP position in...
BC Extra | Mar 12, 2019
Company News

UC strengthens CRISPR IP position with new patent

The USPTO issued a third patent covering fundamental aspects of the CRISPR-Cas9 technology to The Regents of the University of California, the University of Vienna and Emmanuelle Charpentier, strengthening the group's patent position in the...
BC Extra | Feb 8, 2019
Company News

USPTO to grant UC foundational CRISPR patent

A notice of allowance on a core CRISPR patent application will put IP covering the most foundational aspects of the game-changing gene editing technology in the hands of two rival parties. The Regents of the...
BC Week In Review | Nov 2, 2018
Company News

UC Regents issued second CRISPR patent in U.S.

The Regents of the University of California, the University of Vienna and Emmanuelle Charpentier were granted a patent by the U.S. Patent Office covering use of guide RNA formats in CRISPR-Cas9 gene editing technology. The...
BC Innovations | Nov 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: October 2018

New Therapeutic Targets and Biomarkers: October 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during October. Therapeutic targets are defined as any protein, gene or other molecule...
BC Extra | Oct 30, 2018
Company News

UC Regents issued second CRISPR patent in U.S.

The Regents of the University of California, the University of Vienna and Emmanuelle Charpentier were granted a patent by the U.S. Patent Office covering use of guide RNA formats in CRISPR-Cas9 gene editing technology. The...
Items per page:
1 - 10 of 90